Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease
BioconNSE 1.11 % said it has given exclusive rights to Equillium for developing and commercializing itolizumab in Australia and New Zealand.
Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.
Equillium had originally secured exclusive rights to develop and commercialize itolizumab for the US and Canada markets in May 2017.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Biocon is pleased with the development progress of itolizumab achieved by Equillium so far and has agreed to include Australia and New Zealand within the scope of the licensing agreement. As an innovation-led organization, we are committed to bring novel therapeutics to the market to address unmet patient needs across the world. We look forward to our continued partnership with Equillium as they develop this molecule further for the treatment of severe autoimmune and inflammatory disorders,” Si ..
Source: The Economic Times
